Cervical cancer · Romania and the European Union
Cervical cancer: in 2019, nearly half of Romanian women aged 20–69 said they had never had a screening test
In the EU, nearly one in seven (the 2019 European health survey). In 2023, 1,178 women died of cervical cancer in Romania, more than three a day; Romania has 4% of the EU’s women and 13% of these deaths.
Women like you
Pick an age and where you live: 100 women like you, in Romania and in the EU.
- Never had a test
- Tested in the last three years
- Tested more than three years ago
Screening tests reduce both the number of cases and the number of deaths from cervical cancer (IARC, 2022).
Percentages of women’s own answers in the 2019 European health survey (a cervical smear, or Pap test, as they reported it). They describe women of the chosen age and place, not your personal risk. Place types follow the EU classification of the degree of urbanisation.
Where to get the test free, and how often: the HPV test guide
1,178 women in 2023; at average EU rates there would have been 366#
In 2023, 1,178 women died of cervical cancer in Romania, more than three a day. In the whole European Union the figure was 8,801. Romania has 4.3% of the EU’s women and 13.4% of these deaths. Of the 1,178, 528 were under 65 and 160 under 50.
If Romanian women of each age had died at the average EU rate for that age in the same year, there would have been about 366 deaths. The gap of 812 shows how far Romania is from the EU average. The number does not say how many of these deaths could have been avoided.
Least tested: women with less schooling and lower incomes#
Among all women aged 20–69, 47.4% in Romania had never had a test (a cervical smear, or Pap test), against 13.7% in the EU. The 2019 survey shows large differences between women. Among women aged 20–69 with at most lower-secondary schooling, 66.1% had never had a test; in the EU, 16.5%. Among university graduates, 33.7% in Romania and 10.3% in the EU.
By income, in the lowest fifth 69.2% had never had a test in Romania and 20.7% in the EU; in the highest fifth, 35.4% and 9.2%. The income fifths are those of the survey and are calculated separately in each country. Even in Romania’s highest-income fifth, the share of women who had never had a test (35.4%) is higher than in the EU’s lowest-income fifth (20.7%).
Over time: Romania’s share of EU deaths is falling, and the national programme reaches few women#
Romania’s share of EU deaths was highest in 2014, 17.6%; it was 16.0% in 2019 and 13.4% in 2023. Its share of the EU’s women stayed between 4.3% and 4.6%. The lowest age-standardised rate among Romania’s regions (calculated as if all regions had the same age structure) is 9.4 deaths per 100,000 women (Bucharest-Ilfov, the capital region, average 2021–2023); in the EU, 3.5.
Romania’s national screening programme covers women aged 25–64. Women tested by a doctor outside the programme are not counted in the official indicator, which is the share tested in the last three years within the national health programmes: 8.0% in 2014, 2.6% in 2018 and 6.2% in 2023. The series starts in 2014, the first year with three full years of data. In Romania the national health programmes are run by the Ministry of Health and paid from the national health insurance fund; the guide linked above explains how a woman gets the test free, with a family doctor’s referral to a gynaecologist who has a contract with the insurance fund. In the European survey, 62.1% of Romanian women aged 20–69 said in 2014 that they had never had a test; in 2019, 47.4%.
What the data show and do not show about testing#
The International Agency for Research on Cancer (IARC) concluded in 2022, from the existing studies, that screening with cytology or with an HPV test reduces both the number of cases and the number of deaths from cervical cancer. The data on this page cannot explain why Romania has more deaths than other countries. The evidence that testing helps comes from the studies IARC reviewed.
The 27 EU countries were compared: the share of women who had never had a test (2019) and the age-standardised death rate (2019–2021). No clear relationship appears. In Latvia, 3.4% of women had never had a test and there are 9.8 deaths per 100,000; in the Netherlands, 21.4% and 2.4. Romania is first on both. This does not mean that testing does not help: the answer “never” does not show at what age each country’s programme starts or what happens after an abnormal test, and the tables do not show why countries differ.
The 2019 survey records what women reported, about cervical smears; the HPV test began to replace the smear only after 2019 (details in the guide). The figures on deaths are the latest published by Eurostat.
Sources and method#
Deaths come from the Eurostat table by age (ICD-10 code C53, women, by residence) and population from the Eurostat population-by-age table. The EU total is the sum of the 27 member states; the aggregate table was compared with the country sum. The relationship between countries was measured with the Spearman rank correlation: 0.02. “Expected” deaths apply the EU age-specific rate of the same year to the number of Romanian women of the same age; ages 90 and over are one group. For ages 75 and over, the EU population is obtained by subtracting the women under 75 from the total, because Eurostat does not publish single ages above 85 for 2011–2020.
The age-group rates beside the grids pool 2019–2023 and use the survey’s age groups. The age-standardised rate is the one published by Eurostat. The 2019 survey percentages are those published by Eurostat; for each age and place the three answers sum to 100%.
- Eurostat, deaths from cervical cancer by age group (hlth_cd_aro) and age-standardised rates by region (hlth_cd_asdr2)
- Eurostat, population by age (demo_pjan)
- Eurostat, European Health Interview Survey 2019: last cervical smear by age, degree of urbanisation, education and income (hlth_ehis_pa8u, pa8e, pa8i)
- Eurostat, screening programmes (hlth_ps_prev) and the National Institute of Statistics (INS), indicator ZBD0331 (2012–2020)
- IARC, Handbooks of Cancer Prevention, vol. 18, Cervical Cancer Screening (2022)